NVS - Regenxbio: Revisiting This Gene Therapy 'Picks And Shovels' Play
Shares of Regenxbio (RGNX) have risen by 190% since I initially uncovered and recommended a position in this gene therapy pioneer in 2016. The stock has appreciated by just 52% since my February 2018 update piece.
With the recently announced acquisition of collaboration partner Audentes Therapeutics (BOLD) by Astellas Pharma for $2.7 billion (also a prior recommendation), I thought it's time to revisit this gene therapy "picks and shovels" play.
Chart
Figure 1: RGNX daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a